The United States Trade Representative (USTR) has responded to a petition dealing with price controls imposed on coronary artery stents in India, but a representative of device makers in India have accused the Advanced Medical Technology Association of acting "in poor taste," while others in India claim the AdvaMed petition is a case of bullying.

HONG KONG – Foresee Pharmaceuticals Co. Ltd. and TRPharm Ilac Sanayi Tic. A/S have entered an exclusive licensing and distribution agreement for the commercialization of Foresee's most advanced asset, FP-001, a luteinizing hormone-releasing hormone-agonist therapy for prostate cancer, in Turkey and certain Middle East countries.

HONG KONG – Foresee Pharmaceuticals Co. Ltd. and TRPharm Ilac Sanayi Tic. A/S have entered an exclusive licensing and distribution agreement for the commercialization of Foresee’s most advanced asset, FP-001, a luteinizing hormone-releasing hormone-agonist therapy for prostate cancer, in Turkey and certain Middle East countries.

HONG KONG – Generon Corp. (Shanghai) Ltd. has reached an agreement with the FDA under a special protocol assessment (SPA) regarding the second pivotal global phase III study design of its chemotherapy-induced neutropenia (CIN) treatment.

HONG KONG – Chinese biotech company Hybio Pharmaceutical Co. recently received approval from the CFDA to conduct clinical trials for its generic version of GLP-1 analogue liraglutide.

HONG KONG – YL Biologics Ltd. has inked a licensing deal to distribute a biosimilar for the treatment of anemia by Korea's CJ Healthcare Ltd. in Japan. The drug, CJ-40001, is CJ Healthcare's version of Amgen Inc.'s Aranesp (darbepoetin alfa).